CA3230418A1 - Adaptation of platform hosts to igf- media - Google Patents

Adaptation of platform hosts to igf- media Download PDF

Info

Publication number
CA3230418A1
CA3230418A1 CA3230418A CA3230418A CA3230418A1 CA 3230418 A1 CA3230418 A1 CA 3230418A1 CA 3230418 A CA3230418 A CA 3230418A CA 3230418 A CA3230418 A CA 3230418A CA 3230418 A1 CA3230418 A1 CA 3230418A1
Authority
CA
Canada
Prior art keywords
cell
cells
igf
protein
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230418A
Other languages
English (en)
French (fr)
Inventor
Kristine Marie Daris
Huong Thi Ngoc LE
Eric GISLASON
Trent Phillip Munro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3230418A1 publication Critical patent/CA3230418A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3230418A 2021-09-10 2022-09-09 Adaptation of platform hosts to igf- media Pending CA3230418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242623P 2021-09-10 2021-09-10
US63/242,623 2021-09-10
PCT/US2022/076158 WO2023039502A1 (en) 2021-09-10 2022-09-09 Adaptation of platform hosts to igf- media

Publications (1)

Publication Number Publication Date
CA3230418A1 true CA3230418A1 (en) 2023-03-16

Family

ID=84053053

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230418A Pending CA3230418A1 (en) 2021-09-10 2022-09-09 Adaptation of platform hosts to igf- media

Country Status (13)

Country Link
US (1) US20230082811A1 (https=)
EP (1) EP4399225A1 (https=)
JP (1) JP2024533319A (https=)
KR (1) KR20240054986A (https=)
CN (1) CN117897401A (https=)
AR (1) AR127022A1 (https=)
AU (1) AU2022344262A1 (https=)
CA (1) CA3230418A1 (https=)
CL (1) CL2024000698A1 (https=)
IL (1) IL310660A (https=)
MX (1) MX2024002959A (https=)
TW (1) TW202328442A (https=)
WO (1) WO2023039502A1 (https=)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5262308A (en) * 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
ES2227669T3 (es) 1996-01-11 2005-04-01 Immunex Corporation Elementos de secuencia que aumentan la expresion (ease) para sistemas de expresion de eurocariotas.
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP1614755A1 (en) 2004-07-07 2006-01-11 ARTEMIS Pharmaceuticals GmbH Target transgenesis of short hairpin RNA expression cassette using recombinase mediated cassette exchange
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
JP6195191B2 (ja) 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
US10973069B2 (en) 2017-08-07 2021-04-06 Lg Electronics Inc. Method and apparatus for keeping DC configuration
EP3441471A1 (en) * 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines

Also Published As

Publication number Publication date
AU2022344262A1 (en) 2024-02-22
CN117897401A (zh) 2024-04-16
AR127022A1 (es) 2023-12-13
IL310660A (en) 2024-04-01
US20230082811A1 (en) 2023-03-16
CL2024000698A1 (es) 2024-09-06
JP2024533319A (ja) 2024-09-12
KR20240054986A (ko) 2024-04-26
WO2023039502A1 (en) 2023-03-16
TW202328442A (zh) 2023-07-16
MX2024002959A (es) 2024-03-27
EP4399225A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
JP6621744B2 (ja) 組換えタンパク質のグリコシル化を調節するためのモネンシンの使用
US20230323287A1 (en) Overexpression of insulin-like growth factor receptor mutants to modulate igf supplementation
US20230082811A1 (en) Adaptation of platform hosts to igf- media
US20250027052A1 (en) Vectors incorporating a combination of promoters driving selectable marker expression
WO2025155776A1 (en) Expression vector systems with two copies of light chain
WO2025184493A1 (en) Dual selection expression vector systems for multi-chain biologics
WO2025155774A2 (en) Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241104

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250820

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260312